Trastuzumab plus vinorelbine or taxane c
β
Harold J. Burstein; Aparna Keshaviah; Ari D. Baron; Ronald D. Hart; Rosemary Lam
π
Article
π
2007
π
John Wiley and Sons
π
English
β 157 KB
## Abstract ## BACKGROUND. The optimal trastuzumabβbased chemotherapy regimen for HER2βoverexpressing, metastatic breast cancer is not known. The __tr__astuzumab __a__nd __vi__norelbine __o__r __ta__xane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was designed to compare